Bristol Myers-backed TORL Raises $158M to Advance Antibody-Drug Conjugates (ADCs) in Clinical Trials

1. TORL, a company backed by Bristol Myers Squibb, has secured $158 million in funding.
2. The funding is intended to support the advancement of TORL's Antibody-Drug Conjugates (ADCs) through clinical trials.
3. This funding news was reported by Fierce Biotech in March 2024.
4. The investment aims to strengthen TORL's position in the development of innovative cancer therapies using ADCs.

Please note that the information provided is based on the search results from April 16, 2024, which reflect the most recent available data at that time.